BALTIMORE, MD / ACCESSWIRE / January 7, 2021 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has released a new company report on Global WholeHealth Partners Corporation (OTC PINK:GWHP). GWHP is an emerging rapid diagnostic point-of-care (PoC) provider of test kits for hospitals, physicians' offices, and medical clinics in the US and abroad. Global WholeHealth Partners Corp (OTC PINK:GWHP) offers all the formats for testing COVID-19. Separately, An EUA filing with the FDA for GWHP's Antigen Rapid IgA test for COVID-19 is pending approval. This update carries a price target. To view the new research update, previous reports, report, along with disclosures and disclaimers, or to download it in its entirety, please visit https://bit.ly/3s6V5zt.
GWHP is set to emerge as a major provider of COVID-19 diagnostics test kits, an estimated $5.1 billion market. The Company has filed an Emergency Use Application (EUA) with the FDA for its rapid anti-body test with a response pending. In studies performed in 2020, GWHP's diagnostic test produced an accuracy rate of over 97%, prompting the Department of the Navy to place an order for 1000 kits. Once approved, the Made in the USA kit offers advantages over existing tests in use today. These include a relative low cost and rapid PoC results, which removes the main bottleneck to testing processes.
In the Opportunity Research update, analyst Rob Goldman discusses the current environment for GWHP's business along with recent events and capital markets considerations.
Goldman noted, "We view GWHP as one of the industry's top COVID-19 testing companies. GWHP is one of only a few firms to offer all the formats for testing COVID-19. The recent sell-off in GWHP's stock appears to offer a rare entry point for opportunistic investors. It seems that investors have focused on vaccines rather tests in recent weeks despite the fact that vaccine deployment is woefully behind schedule. Conversely, the number of daily tests seems to consistently break new records."
"Against this backdrop, it appears that the Street is beginning to pivot back to the importance of diagnostics," according to Goldman. Nearly 264M tests already been performed in the US, indicating testing frequency and easy PoC access appear set to drive sales in the industry, going forward. At current prices, GWHP offers the greatest upside, in our view."
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.
Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published company report on Global WholeHealth Partners Corporation. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Global WholeHealth Partners Corporation ("the Company"). The information includes authorized press releases or legal disclosures made in their filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our report about the Company, we may from time to time include our own opinions about the Company, its business, markets, and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, sector or industry snapshot, podcast interview, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. A Speculative Buy rating for our covered companies is defined as a company that we believe exhibits the potential to generate outsized returns despite inherent, above-average business, market, or financial risk. To download this research report or any of our research, view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research was compensated $5000 by the Company for the production and distribution of this research update, previous reports, and associated press release and distribution, along with $1000 for a podcast interview.
Goldman Small Cap Research
Rob Goldman, Analyst
SOURCE: Goldman Small Cap Research